MIG Fonds

MIG Capital AG, formerly known as MIG Verwaltungs AG, is a German venture capital firm that manages the MIG Fonds, a series of public venture capital funds. Founded in 2004 by Michael Motschmann, Hermann-Josef Lamberti, and Matthias Hallweger, the firm is based in Munich, Germany. Motschmann, an entrepreneur and investor, established the firm to provide private investors with access to unlisted high-tech companies, a market traditionally reserved for institutional investors. MIG Capital focuses on early-stage deep-tech and life sciences companies primarily located in Germany, Austria, and Switzerland. The firm invests in sectors such as biotechnology, medtech, artificial intelligence, quantum technologies, and digital health. Its investment philosophy centers on backing companies with disruptive technologies and strong intellectual property that address significant market needs. The business model involves pooling capital from private investors through the MIG Fonds series and deploying it into a diversified portfolio of startups. Revenue is generated through management fees and carried interest from the funds‘ profits. A notable success in MIG’s portfolio is BioNTech SE, the company that developed one of the first mRNA-based COVID-19 vaccines. MIG Fonds was an early and significant investor in BioNTech, participating in its Series A financing round in 2008 and holding a substantial stake until after the company’s IPO on the Nasdaq. This investment yielded a return of over €750 million for the MIG funds‘ investors, representing one of the most successful venture capital investments in Europe. Other key portfolio companies include Immatics, a developer of T-cell-based immunotherapies, and NavVis, a provider of indoor spatial intelligence technology. Keywords: venture capital, deep-tech, life sciences, early-stage investing, biotechnology, private equity, asset management, medtech, quantum computing, startup financing